AB Science announces a slight delay in the publication of its 2024 half-year financial report

PRESS RELEASE

AB SCIENCE ANNOUNCES A SLIGHT DELAY IN THE PUBLICATION OF ITS 2024 HALF-YEAR FINANCIAL REPORT

THE COMPANY WILL PUBLISH ITS HALF-YEAR FINANCIAL REPORT FOR 2024 ON OCTOBER 7, 2024

Paris, September 30 2024, 6.30pm CET

AB Science SA (Euronext - FR0010557264 - AB) today announced that it has postponed the publication of its financial report for the first half of 2024, initially scheduled for 30 September 2024, to give the auditors time to complete their audit work.

The Company will publish its financial report for the first half of 2024 on Monday 7 October 2024, after trading.

About AB Science
Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action are key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with short term survival or rare or refractory to previous line of treatment.

AB Science has developed a proprietary portfolio of molecules and the Company’s lead compound, masitinib, has already been registered for veterinary medicine and is developed in human medicine in oncology, neurological diseases, inflammatory diseases and viral diseases. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB).

Further information is available on AB Science’s website: www.ab-science.com.

Forward-looking Statements - AB Science
This press release contains forward-looking statements. These statements are not historical facts. These statements include projections and estimates as well as the assumptions on which they are based, statements based on projects, objectives, intentions and expectations regarding financial results, events, operations, future services, product development and their potential or future performance.

These forward-looking statements can often be identified by the words "expect", "anticipate", "believe", "intend", "estimate" or "plan" as well as other similar terms. While AB Science believes these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties that are difficult to predict and generally beyond the control of AB Science and which may imply that results and actual events significantly differ from those expressed, induced or anticipated in the forward-looking information and statements. These risks and uncertainties include the uncertainties related to product development of the Company which may not be successful or to the marketing authorizations granted by competent authorities or, more generally, any factors that may affect marketing capacity of the products developed by AB Science, as well as those developed or identified in the public documents published by AB Science. AB Science disclaims any obligation or undertaking to update the forward-looking information and statements, subject to the applicable regulations, in particular articles 223-1 et seq. of the AMF General Regulations.

For additional information, please contact:

AB Science
Financial Communication & Media Relations
investors@ab-science.com

Attachment

  • CP Décalage Publication Comptes 2024 S1 VEng VF

Ab Science (EU:AB)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Ab Science Charts.
Ab Science (EU:AB)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Ab Science Charts.